Education
About Us
Working with TipRanks
Follow Us
Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
TVRD Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TVRD Stock 12 Month Forecast
Average Price Target
$59.50
▲(94.44% Upside)
| Highest Price Target$78.00 | Average Price Target$59.50 | Lowest Price Target$46.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JonesTrading
$46
Buy
50.33%
Upside
Reiterated
08/28/25
Tvardi Therapeutics: Buy Rating Driven by Promising TTI-101 Trial ProspectsWe see a strong likelihood of TTI-101 showing a competitive profile, representing a major upside catalyst for TVRD. Our base case. As per our KOLs, achieving disease stabilization would be a big win for a novel IPF drug. In our base case, we see FVC stabilization on TTI-101 (+/-1% change from baseline at Wk-12). In comparison, we expect FVC on placebo arm to decline by 2.3-3%, in line with recent comparable Ph2 trials. While cross trial comparisons have caveats, our base case efficacy range for TTI-101 assumes a profile that is at least superior to BMS' admilparant to potentially matching PLRX's bexotegrast (recall that bexotegrast failure was due to safety not efficacy). Following such an outcome, TVRD stock could potentially jump up to 65%, depending on details.
Raymond James
$62
Buy
102.61%
Upside
Reiterated
08/22/25
TR | OpenAI - 4o
$27
Hold
-11.76%
Downside
Reiterated
08/21/25
Cantor Fitzgerald
$52
Buy
69.93%
Upside
Initiated
07/11/25
Piper Sandler
$78
Buy
154.90%
Upside
Initiated
06/12/25
BTIG
$55
Buy
79.74%
Upside
Reiterated
05/27/25
Oppenheimer
$65
Buy
112.42%
Upside
Initiated
05/21/25
Lucid Capital
$42
Buy
37.25%
Upside
Initiated
04/30/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JonesTrading
$46
Buy
50.33%
Upside
Reiterated
08/28/25
Tvardi Therapeutics: Buy Rating Driven by Promising TTI-101 Trial ProspectsWe see a strong likelihood of TTI-101 showing a competitive profile, representing a major upside catalyst for TVRD. Our base case. As per our KOLs, achieving disease stabilization would be a big win for a novel IPF drug. In our base case, we see FVC stabilization on TTI-101 (+/-1% change from baseline at Wk-12). In comparison, we expect FVC on placebo arm to decline by 2.3-3%, in line with recent comparable Ph2 trials. While cross trial comparisons have caveats, our base case efficacy range for TTI-101 assumes a profile that is at least superior to BMS' admilparant to potentially matching PLRX's bexotegrast (recall that bexotegrast failure was due to safety not efficacy). Following such an outcome, TVRD stock could potentially jump up to 65%, depending on details.
Raymond James
$62
Buy
102.61%
Upside
Reiterated
08/22/25
TR | OpenAI - 4o
$27
Hold
-11.76%
Downside
Reiterated
08/21/25
Cantor Fitzgerald
$52
Buy
69.93%
Upside
Initiated
07/11/25
Piper Sandler
$78
Buy
154.90%
Upside
Initiated
06/12/25
BTIG
$55
Buy
79.74%
Upside
Reiterated
05/27/25
Oppenheimer
$65
Buy
112.42%
Upside
Initiated
05/21/25
Lucid Capital
$42
Buy
37.25%
Upside
Initiated
04/30/25
Best Analysts Covering Tvardi Therapeutics
1 Month
xxx
Success Rate
3/4 ratings generated profit
Average Return
+10.35%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +10.35% per trade.
3 Months
xxx
Success Rate
3/4 ratings generated profit
Average Return
+10.00%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +10.00% per trade.
1 Year
Success Rate
4/4 ratings generated profit
Average Return
+14.07%
reiterated a buy rating 2 days ago
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +14.07% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
Average Return
+14.07%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +14.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TVRD Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
6
8
8
6
Buy
0
3
3
3
0
Hold
8
5
4
1
1
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
11
15
16
12
7
Each month's total comprises the sum of three months' worth of ratings.
TVRD Financial Forecast
TVRD Stock Forecast FAQ
What is TVRD’s average 12-month price target, according to analysts?
Based on analyst ratings, Tvardi Therapeutics’s 12-month average price target is 59.50.
What is TVRD’s upside potential, based on the analysts’ average price target?
Tvardi Therapeutics has 94.44% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TVRD a Buy, Sell or Hold?
Tvardi Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Tvardi Therapeutics’s price target?
The average price target for Tvardi Therapeutics is 59.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $78.00 ,the lowest forecast is $46.00. The average price target represents 94.44% Increase from the current price of $30.6.
The highest analyst price target is $78.00 ,the lowest forecast is $46.00. The average price target represents 94.44% Increase from the current price of $30.6.
What do analysts say about Tvardi Therapeutics?
Tvardi Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of TVRD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.